PHILIPPE BIERLING, M.D.; CATHERINE CORDONNIER, M.D.; NAJIB DUEDARI, M.D.; JEAN-PAUL VERNANT, M.D.; JACQUES LEIBOWITCH, M.D.; DOMINIQUE MATHEZ, M.D.
To the editor: The acquired immunodeficiency seen after bone marrow transplantation and that due to infection with the lymphadenopathy-associated virus/human T-lymphotropic virus type HI (LAV/HTLV-III) have many clinical and immunologic features in common. Marrow transplant recipients are at risk of LAV/HTLV-III infection given the considerable amount of transfused blood products they receive. A retrospective study was conducted in our institution to determine the role of LAV/HTLV-III in the immunodeficiency seen after bone marrow transplantation.
Fifty unselected patients, for whom a serum sample collected at least 100 days after bone marrow transplantation was available, were included. All patients received an allogeneic
PHILIPPE BIERLING, CATHERINE CORDONNIER, NAJIB DUEDARI, JEAN-PAUL VERNANT, JACQUES LEIBOWITCH, DOMINIQUE MATHEZ. Lymphadenopathy-Associated Virus/Human T-Lymphotropic Virus Type III in Allogeneic Bone Marrow Transplantation. Ann Intern Med. 1986;104:131–132. doi: 10.7326/0003-4819-104-1-131
Download citation file:
Published: Ann Intern Med. 1986;104(1):131-132.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use